Medical Subject Headings (MeSH): Biosimilar Pharmaceuticals
Biosimilars are pharmaceutical products that are highly similar to and have been derived from an already licensed biologic medicine. Biosimilars are developed to be highly similar to the reference product in terms of quality, safety, and efficacy. They are typically used as an alternative to the reference product to treat the same medical condition.
The use of biosimilars in healthcare can provide several benefits, including increased access to biologic medicines, which can be expensive and may not be available to all patients, and lower healthcare costs. In addition, the development and use of biosimilars can encourage innovation and competition within the pharmaceutical industry, which can drive down prices and improve patient access to innovative treatments.
However, the development and approval of biosimilars can be complex, as they must undergo rigorous testing to demonstrate that they are highly similar to the reference product and meet the same high standards for safety and efficacy. In addition, there may be concerns about the interchangeability of biosimilars with the reference product, which refers to the ability to switch between the two products without affecting the safety or efficacy of treatment.
Overall, the use of biosimilars in healthcare is an important and growing area that can help to improve patient access to innovative treatments and lower healthcare costs.
Know anyone building innovative solutions that belong in this 'Biosimilar Pharmaceuticals'?
Exploring best practice: industry regulations, end-to-end transportation, digitalization, sustainability and mitigating risks. This important industry event will bring together professionals in pharma, biopharma and biotech companies specializing in: cold chain, supply chain, logistics, procurement, quality assurance and temperature controlled logistics. Our distinguished speakers will tackle the most pressing industry challenges, will share cutting-edge technologies and will help you prepare for the future by addressing game-changing innovations. Join us for what will be an unmissable event in the industry calendar, one that will help you benchmark your strategies and be more effective in this dynamic industry.
Comprehensive analytical support has been crucial to the global success of mRNA medicines. As drug development timelines become more demanding, accessing novel, optimised, and high-throughput analytical methods is essential to guarantee the approval and commercialisation of safe and effective mRNA therapeutics and vaccines.
The inaugural mRNA Analytical Development Summit Europe is the only industry-dedicated forum to showcase critical expertise and the latest techniques in optimised analytics for leading European biopharma. Taking place in Berlin this August, this meeting highlights the importance of advanced analytical approaches and adherence to regulatory requirements, as the European market continues to capitalise on these strategies.
Join the main industry players as they navigate through their case studies and share their experiences!
The First Industry Forum for Translational Experts, Neuroscience Drug Sponsors and Biomarker Technology Developers to Transform Earlier Assessment of AD, PD, ALS and MS. Development and integration of validated, inexpensive, non-invasive, and reliable fluid and imaging biomarkers are critical to advance neurodegenerative and neuro-immunological drug candidates through clinical trials. Built to provide cutting-edge insights across emerging biomarker technologies and address the current translational bottleneck hindering your pipeline's success: the inaugural Fluid and Imaging Biomarkers in Neuroscience Summit is an unrivaled new opportunity to evaluate the latest biomarker research across AD, PD, MS and ALS, in one highly focused forum.
The most anticipated event of the mRNA calendar year is back with a bang! The mRNA-Based Therapeutics Summit is returning for its 3rd year this July as the one-stop-shop for all your mRNA needs, showcasing exclusive new data from the movers and shakers in the mRNA industry. 500+ industry pioneers from the likes of the FDA, Pfizer, Moderna, BioNTech, Sanofi and many more are joining the world's only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines.
Expect 100+ world-class speakers from large pharma, innovative biotechs, and key opinion leaders of academia, 5 dedicated tracks and 3 days of immersive content on discovery, translation, clinical development, chemistry, manufacturing and controls (CMC) and logistics to overcome industry hurdles of optimized dosing, targeted delivery, safety and scalability to achieve regulatory success in infectious and rare diseases, cancer and beyond!
Welcome to the 2nd Process Development for Cell Therapies Summit: Driving Process Automation, Affordability and Scalability for Global Cell Therapies
Join 80+ experts from BMS, Janssen, ArsenalBio, Bluebird Bio, Notch Therapeutics, Bayer, and more, looking to streamline cell therapy process development by sharing best practices and pre-competitive learnings to supercharge your pipeline development.
This is your opportunity to engage with the process development for the cell therapy industry, gain insights into best practices, and progress in a pre-competitive space.
. REVIEW The Challenges, Roles and Emerging Trends in Process Development for Cell Therapies with Janssen, 2Seventy Bio and Immatics Biotechnology
. INNOVATE analytical methods and digital platforms to ensure product quality and efficacy with Arsenal Bio and Caribou Biosciences
. OPTIMIZE scalability in an automated approach to reduce human error throughout phase development with Bayer and Glycostem Therapeutics
. MINIMIZE the time of process while maximizing quality of yield with Bristol Myers Squibb and Carisma Therapeutics
. EXAMINE the technical advancements required to drive process development forward in both upstream and downstream processes with Notch Therapeutics and Tmunity Therapeutics
The Drug Safety Summit provides a holistic view of drug safety science, bringing together leaders in Risk Evaluation and Mitigation Strategy, Pharmacovigilance, and Regulatory Affairs to share current best practices and experiences in developing safety/regulatory strategies for different regions across the globe. With a dedicated focus on REMS and Pharmacovigilance, the Drug Safety Summit allows representatives from across drug safety teams to come together to establish practices that will limit the risks connected to their marketed products.
Better cell culture media, cell lines, and bioreactor strategies are responsible for yielding 10+g/l on a consistent basis. Going forward, companies will continue to implement new technologies and process designs to support emerging therapeutics. Our experts share their personal experiences and insight to help anticipate challenges and chose appropriate technologies to support your production strategies.
Unlocking the Next Wave of Clinically Relevant GPCR Targets
Returning for the 2nd year, the GPCR-Targeted Drug Discovery Summit is the only industry-led meeting of its kind dedicated to congregating the most forward thinking biotechs, established large pharma, and key academic opinion leaders committed to discovering and validating the next wave of GPCR targets across a breadth of indications.
- Welcoming a whole host of exciting new GPCR-focused biotechs onto the agenda, with presentations from Septerna, Tectonic, DJS Antibodies, OKYO Pharma, and On Target Therapeutics
- Increased emphasis on allosteric modulation with 5 talks dedicated to highlighting novel methods of integrating this new ‘modality’ and the potential it holds as an alternative to agnostic and antagonistic targeting
- A brand-new workshop day featuring 3 workshops; workshop A on specific, lesser explored GPCR receptors (adhesion and chemokine) led by 2 key academic leaders, workshop B on allosteric modulation with 3 expert leaders, and workshop C, a deep dive into what venture capitalists are looking for in the GPCR space right now
… as well as covering the most pressing challenges in GPCR-target identification with integration of novel platforms, target validation with improvements being made in in-vitro assay kits, and predictive modelling enhancements made by machine learning and computational technologies.
The 2nd GPCR-Targeted Drug Discovery Summit will equip your team with the knowhow to tackle hurdles in the orphan drug space, elevate understanding of opportunity in dark targets, bias signalling, and the various modalities currently being pursued as novel GPCR drug candidates.
February 21-23, 2023
Drug Developers (Earlybird rates & workshops available) USD 3199.00
Service Providers (Earlybird rates & workshops available) USD 3799.00
Category: Conferences | Science, Health & Medicine | Pharmaceuticals
Speakers: Graeme Milligan, Professor, University of Glasgow, Bryan Roth, Professor of Pharmacology, UNC School of Medicine, Jeff Finer, Chief Executive Officer, Septerna, Kate Lansu, Senior Scientist, Eli Lilly & Company, Laurent Sabbagh, Head of Biology, DOMAIN Therapeutics
Dates and Time: Starts: Tue, Feb 21, 2023 ( 8:00 AM) and Ends: Thu, Feb 23, 2023 ( 5:00 PM)
Venue details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, Massachusetts, 02111, United States
Explore significant advancements in clinical trial design to push medicinal phage therapies to the clinic, CRISPR-based gene editing to improve functionality, the rise of lytic technologies, and alternative potential for phage technologies beyond human health. This is the conference of the year for biopharma, clinicians and consumer product developers to harness the safety and efficacy of phages.
Whether you're at the forefront of the field or emerging into phage therapy for the first time, the 5th Bacteriophage Therapy Summit is the key networking platform that enables you to meaningfully apply phage science and prove commercial success.
Speakers: Bob Blasdel, Director - Research, Vesale Pharma , Danish Malik, Reader Industrial Biology, Loughborough University, Edward Burd, Senior Vice President Regulatory Affairs, BiomX, Iddo Nadav Weiner, Director and Head of Software, BiomX, Lorenzo Corsini, Co-Founder and Chief Executive Officer, Phagomed, Minmin Yen, Chief Executive Officer and Co-Founder, PhagePro, Vincent Fischetti, Professor and Head of Lab, The Rockefeller University Viviana Clavijo, Chief Executive Officer, Sciphage, Clara Leandro, Head of Infection, TechnoPhage SA, David Harper, Chief Executive Officer, etc.
Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Discovery
Date and Time: 21st February 2023 at 9:00 am to 23rd February 2023 at 5:00 pm
Over the past couple of years, the engineered biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially.
The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.
Returning for the 2nd year, the Synthetic Biology-Based Therapies Summit is the industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.
Learn from industry trailblazers at Arsenal Biosciences, bit.bio, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.
Conference + Workshop Day - Industry Pricing USD 3497.00
Conference Only - Industry Pricing USD 2599.00
Conference + Workshop Day - Service Provider Pricing USD 4297.00
Conference Only - Service Provider Pricing USD 3199.00
Conference + Workshop Day - Academic Pricing USD 2897.00
Conference Only - Academic Pricing USD 2199.00
Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development
Dates and Time: Starts: Tue, Dec 13, 2022 ( 9:00 AM) and Ends: Thu, Dec 15, 2022 ( 5:00 PM)
Venue details: Embassy Suites by Hilton Boston at Logan Airport, 207 Porter Street, Boston, Massachusetts, 02128, United States
This webinar will recommend strategies to efficiently execute pharma development & manufacturing programs. The speakers will discuss a real-life example about how appropriate planning and judicious risk assessment favorably impacted a project timeline for a virtual pharmaceutical company. The speakers will share the successful tactics that shortened the project by performing tasks in parallel, allowing the client to maintain their commitments to their stakeholders. They will also identify what risks to the timeline should be avoided.
It’s no secret that the COVID-19 pandemic drove a rapid increase in the adoption of decentralized clinical trials (DCTs) across the life sciences industry. Utilizing digital technologies has demonstrated ample benefits to sponsors, study teams and importantly, patients. These benefits include increasing efficiency across clinical operations and data management, simplifying the sponsor technology ecosystem, reducing patient and site burden, accelerating timelines, providing access to real-time data and insights, improving access to more diverse patient populations and more.
The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important.
This year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality and efficacy of gene therapy products.
Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges.
If you work in quality control, quality assurance, or process development - we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support.
Whether you're working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.
November 28 to December 1, 2022
The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our